Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
AI-driven innovation in life sciences: Data as data should be
Posted on November 17th, 2021 by Ann-Marie Roche in AI & Data
Your AI applications are only as strong as your data. This is why Elsevier strives to make data not only align with FAIR usability principles but also be maximized for trustworthiness and relevance. In this way we can confidently offer the full potential of data science in an easy-to-use manner – from data acquisition and preparation, to AI application and interpretation.
(more…)AI-driven innovation in Life Sciences: Data Science & AI amplifies your innovative drug R&D capabilities
Posted on November 4th, 2021 by Ann-Marie Roche in AI & Data
If you work in Life Sciences & Health, you’re likely aware of what Data Science and AI can bring to the table when it comes to sparking innovation. However, if you are not Big Pharma, it’s the how that slows down most LSH companies and organizations. We believe that Elsevier’s road-tested data and semantic technologies can address the challenges of Life Science data.
(more…)Finding drug information can be hard – healthcare providers need digital solutions
Posted on October 5th, 2021 by Ann-Marie Roche in Medical Information
The digital transformation in our world was already happening quite rapidly in recent years, but then the COVID-19 pandemic accelerated many aspects of it. Not only did schools and businesses have to learn to function online, but everything from doctor’s visits to dance parties were frequently being conducted on the internet. But even as many sectors have made the digital transition, some areas have continued to lag behind.
(more…)AI precision medicine accelerates the search for rare disease treatment
Posted on September 20th, 2021 by Ann-Marie Roche in AI & Data
AI and precision medicine are both changing drug discovery and development as we know it. Precision medicine that is powered by AI stands to be transformative, especially for the treatment of rare diseases. Elsevier was recently part of a collaboration that sought to demonstrate how AI precision medicine could lead researchers to new treatments for brain tumors faster.
(more…)
